Christopher James Stevens - Aug 4, 2025 Form 4 Insider Report for ROCKET PHARMACEUTICALS, INC. (RCKT)

Role: Chief Operating Officer
Signature: /s/ Martin Wilson, as attorney-in-fact for Christopher James Stevens
Stock symbol: RCKT
Transactions as of: Aug 4, 2025
Transactions value $: $0
Form type: 4
Date filed: 8/6/2025, 04:11 PM
Previous filing: Aug 4, 2025
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Stevens Christopher James	Chief Operating Officer	C/O ROCKET PHARMACEUTICALS, INC., 9 CEDARBROOK DRIVE, CRANBURY	/s/ Martin Wilson, as attorney-in-fact for Christopher James Stevens	2025-08-06	0002079768

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	RCKT	Common Stock	Award	$0	+407K		$0.00	407K	Aug 4, 2025	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	RCKT	Stock Option (Right to Buy)	Award	$0	+554K		$0.00	554K	Aug 4, 2025	Common Stock	554K	$3.07	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Holdings are Restricted Stock Units ("RSUs") that convert to common stock on a one-for-one basis. One-third (1/3) of such RSUs will become fully vested on August 4, 2026, with the remaining shares vesting in equal quarterly installments over the following two years.
F2	This option represents a right to purchase a total of 554,071 shares of the Issuer's common stock, one-third of which will become fully vested and exercisable on August 4, 2026, with the remaining shares vesting in equal quarterly installments over the following two years, subject to the reporting person's continued employment with the Issuer.